RxDoctor Payments Data

Robyn Kempf, PA

Physician Assistant · Orlando, FLNPI 1003129107

Payments from drug & device makers

$536in general payments, 2019–2025

Across 19 payments — averaging $28.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$236
  • Medtronic$146
  • E.r. Squibb & Sons, L.L.C.$47
  • Organogenesis Inc.$36
  • Novartis$23
  • Boston Scientific$17
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$536100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$536 in reported general payments places this provider in the 50th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$471,973
Medicare patients
2,324
Services billed
5,603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$65,222
XareltoRivaroxaban55$57,428
EntrestoSacubitril/Valsartan32$33,876
ClopidogrelClopidogrel Bisulfate105$1,126
Valsartan37$840
Amlodipine Besylate88$775
Metoprolol Succinate45$696
Carvedilol89$638
Nifedipine ErNifedipine31$592
Cilostazol31$504
Atorvastatin Calcium71$470
Hydralazine Hcl28$416
Rosuvastatin Calcium50$397
Simvastatin26$311
Losartan Potassium41$304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$236$57,42855 claims
NovartisEntresto$23$33,87632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →